Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

These stories show how volatility in global markets is pushing manufacturers to make painful workforce decisions.

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

The latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the ...

Haleon Pakistan has announced a fresh investment of $12 million to expand its manufacturing capacity, focusing on scaling up ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and ...

Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...

A report new Intel CEO Lip-Bu Tan is considering costly changes to the company's chip manufacturing business rattled shares this week. Monitor these key chart levels.

Intel's new CEO Lip-Bu Tan is considering a shift in the manufacturer's contract chip-making business, a change that could cost Intel billions, according to Reuters. ...

Intel's new chief executive is exploring a big change to its business to win major customers, two people familiar with the matter told Reuters, in a potentially expensive shift. Alex Cohen has more.